Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T83193 Target Info
Target Name Transient receptor potential cation channel V1 (TRPV1)
Synonyms Vanilloid receptor 1; VR1; TrpV1; Transient receptor potential cation channel subfamily V member 1; Osm-9-like TRP channel 1; OTRPC1; Capsaicin receptor
Target Type Successful Target
Gene Name TRPV1
Biochemical Class Transient receptor potential catioin channel
UniProt ID
TRPV1_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2013096226
Title Trpv1 Antagonists.
Abstract Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed. The compounds of formula (I) are useful as TRPV1 antagonists.
Applicant(s) Abbvie Inc
Representative Drug(s) D0A0YI Drug Info IC50 = 20 nM Click to Show More [1]
2 D0NB5M Drug Info IC50 = 50 nM [1]
Patent ID WO2013096223
Title Trpv1 Antagonists.
Abstract Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Applicant(s) Abbvie Inc
Representative Drug(s) D0JC8L Drug Info IC50 = 7 nM Click to Show More [1]
2 D0R9RP Drug Info IC50 = 13 nM [1]
3 D0EV3G Drug Info IC50 = 16 nM [1]
4 D0A3XC Drug Info IC50 = 26 nM [1]
5 D0F4DI Drug Info IC50 = 36 nM [1]
6 D0IR7H Drug Info IC50 = 40 nM [1]
7 D05SWL Drug Info IC50 = 47 nM [1]
8 D0M4WY Drug Info IC50 = 60 nM [1]
Patent ID WO2013068467
Title Substituted Pyrazolyl-Based Carboxamide and Urea Derivatives Bearing A Phenyl Moiety Substituted with A Co-Containing Group As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a CO-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D0MU3S Drug Info IC50 = 0.3 nM Click to Show More [1]
2 D0IN5E Drug Info IC50 = 0.5 nM [1]
Patent ID WO2013068462
Title Substituted Pyrazolyl-Based Carboxamide and Urea Derivatives Bearing A Phenyl Moiety Substituted with An N-Containing Group As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (R) bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D0P9KJ Drug Info IC50 = 0.3 nM Click to Show More [1]
2 D0DE5K Drug Info IC50 = 0.7 nM [1]
3 D0IU1H Drug Info IC50 = 0.9 nM [1]
Patent ID WO2013068461
Title Substituted Pyrazolyl-Based Carboxamide and Urea Derivatives Bearing A Phenyl Moiety Substituted with An O-Containing Group As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D04FRL Drug Info IC50 = 0.2 nM Click to Show More [1]
2 D0K4SZ Drug Info IC50 = 0.7 nM [1]
Patent ID WO2013045451
Title Amine Substituted Methanesulfonamide Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to amine substituted methanesulfonamide derivatives of formula (I) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D0JX4I Drug Info IC50 = 1 nM Click to Show More [1]
2 D0O9GI Drug Info IC50 = 1 nM [1]
Patent ID WO2013045447
Title Aryl or N-Heteroaryl Substituted Methanesulfonamide Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives of Formula (I) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D01PLJ Drug Info IC50 = 1 nM Click to Show More [1]
2 D0J9CS Drug Info IC50 = 3 nM [1]
Patent ID WO2013021276
Title Trpv1 Antagonists Including Dihydroxy Substituent and Uses Thereof.
Abstract The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof wherein Ar1, Ar2, L1 L2, X, R3, R22, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I), and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I).
Applicant(s) Purdue Pharma Lp
Representative Drug(s) D0IK1S Drug Info IC50 = 29 nM Click to Show More [1]
2 D01LGQ Drug Info IC50 = 30 nM [1]
3 D0F3HP Drug Info IC50 = 32 nM [1]
Patent ID WO2013013817
Title Substituted Heterocyclic Aza Derivatives.
Abstract The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D07EGF Drug Info IC50 = 1 nM Click to Show More [1]
2 D0F5NQ Drug Info IC50 = 1 nM [1]
Patent ID WO2013013816
Title Substituted Bicyclic Aromatic Carboxamide and Urea Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D03QAW Drug Info IC50 = 0.1 nM Click to Show More [1]
2 D00QEZ Drug Info IC50 = 0.4 nM [1]
Patent ID WO2013013815
Title Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D07FIY Drug Info IC50 = 0.6 nM Click to Show More [1]
2 D0P5SB Drug Info IC50 = 1 nM [1]
Patent ID WO2012176061
Title Trpv1 Antagonists Including Dihydroxy Substituent and Uses Thereof.
Abstract The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.
Applicant(s) Purdue Pharma Lp
Representative Drug(s) D05RBF Drug Info IC50 = 40 nM Click to Show More [1]
2 D0KF3A Drug Info IC50 = 96 nM [1]
Patent ID WO2012134943
Title Trpv1 Antagonists.
Abstract Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, (I) wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Applicant(s) Abbvie Inc
Representative Drug(s) D06VYF Drug Info IC50 = 2 nM Click to Show More [1]
2 D08ICT Drug Info IC50 = 2.3 nM [1]
3 D0HE7X Drug Info IC50 = 3.3 nM [1]
4 D0KB2Z Drug Info IC50 = 4 nM [1]
5 D0C1MZ Drug Info IC50 = 5 nM [1]
6 D0C8ZZ Drug Info IC50 = 5.4 nM [1]
7 D00YXA Drug Info IC50 = 5.6 nM [1]
8 D0R8GA Drug Info IC50 = 8.2 nM [1]
9 D0ON4M Drug Info IC50 = 10 nM [1]
10 D02OAH Drug Info IC50 = 11 nM [1]
11 D0O7IQ Drug Info IC50 = 12 nM [1]
12 D0IP5E Drug Info IC50 = 29 nM [1]
13 D0N9FJ Drug Info IC50 = 30 nM [1]
14 D0GZ4G Drug Info IC50 = 64 nM [1]
Patent ID WO2012072512
Title N-Cyclobutyl-Imidazopyridine or -Pyrazolopyridine Carboxamides As Trpv1 Antagonists.
Abstract A compound of formula (I) wherein X1 represents a hydrogen atom, or a CH2OH group X2 represents a hydrogen atom, a fluorine atom, an OCH3 group or a CH2OH group, and at least one of X1 and X2 is hydrogen Y represents a carbon atom and Z represents a nitrogen atom or Y represents a nitrogen atom and Z represents a carbon atom; R1 represents a halogen atom, a C1-4 alkyl group, a trifluoromethyl group or a trifluoromethoxy group, and R2 are R3 each independently selected from a hydrogen atom, a halogen atom, a C1-4 alkyl group, a trifluoromethyl group or a trifluoromethoxy group; or a pharmaceutically acceptable salt or solvate thereof.
Applicant(s) Glaxo Group Limited
Representative Drug(s) D0IT4N Drug Info IC50 = 0.79 nM Click to Show More [1]
2 D04HCS Drug Info IC50 = 1.26 nM [1]
3 D03ZOZ Drug Info IC50 = 2 nM [1]
4 D0O6VU Drug Info IC50 = 3.98 nM [1]
5 D00ODY Drug Info IC50 = 6.31 nM [1]
Patent ID WO2012050380
Title Novel Pyridyl Benzoxazine Derivatives, Pharmaceutical Composition Comprising The Same, and Use Thereof.
Abstract Discloses is a benzoxazine benzimidazole derivative, represented by Chemical Formula 1, functioning as an antagonist to the vanilloid receptor-1, a pharmaceutical composition comprising the same, and the use thereof. The benzoxazine benzimidazole derivative can be useful for preventing or treating a disease associated with antagonistic activity of vanilloid receptor-1, without hyperthermia.
Applicant(s) Daewoong Pharmaceutical Co., Ltd
Representative Drug(s) D03VXP Drug Info IC50 = 20 to 100 nM Click to Show More [1]
2 D0G6IQ Drug Info IC50 < 20 nM [1]
Patent ID WO2012045729
Title Imidazo [1, 2 -A] Pyridine and Pyrazolo [1, 5 -A] Pyridine Derivatives As Trpv1 Antagonists.
Abstract A compound of formula of formula (I) wherein A represents a single bond, a CH2 group or a CH (Me) group; X1 represents a hydrogen atom, a fluorine atom or a methyl group; X2 represents a hydrogen atom, a fluorine atom, a methyl group or a CH2OH group; X3 represents a hydrogen atom, a fluorine atom or a CH2OH group, and at least two of X1, X2 and X3 are hydrogen; Y represents a C atom and Z represents a N atom or Y represents an N atom and Z represents a C atom. R1 represents a halogen atom, a C1-4 alkyl group, a trifluoromethyl group or a trifluoromethoxy group, and R2 and R3 are each independently selected from a hydrogen atom, a halogen atom, a C1-4 alkyl group, a trifluoromethyl group or a trifluoromethoxy group. or a pharmaceutically acceptable salt or solvate thereof. salt or solvate thereof.
Applicant(s) Glaxo Group Limited
Representative Drug(s) D0O0UG Drug Info IC50 = 12.59 nM Click to Show More [1]
2 D0C9FN Drug Info IC50 < 15.58 nM [1]
Patent ID WO2011162409
Title Compounds Having Trpv1 Antagonistic Activity and Uses Thereof.
Abstract The invention relates to compounds of Formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.
Applicant(s) Shionogi & Co., Ltd
Representative Drug(s) D0D2CF Drug Info IC50 = 1 nM Click to Show More [1]
2 D0A8LU Drug Info IC50 = 10 nM [1]
3 D0PT0U Drug Info IC50 = 12 nM [1]
4 D05SMP Drug Info IC50 < 50 nM [1]
5 D07FWF Drug Info IC50 < 50 nM [1]
6 D08YAL Drug Info IC50 < 50 nM [1]
7 D0C5NT Drug Info IC50 < 50 nM [1]
8 D0E0SA Drug Info IC50 < 50 nM [1]
Patent ID WO2010127856
Title Substituted Phenylureas and Phenylamides As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted phenylureas and phenylamides of formula (I), to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.
Applicant(s) Robert Bahrenberg, et al
Representative Drug(s) D07EAV Drug Info IC50 = 0.1 nM Click to Show More [1]
2 D09ZWU Drug Info IC50 = 0.1 nM [1]
Patent ID WO2010127855
Title Substituted Aromatic Carboxamide and Urea Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D0TZ2W Drug Info IC50 = 0.07 nM Click to Show More [1]
2 D06JHW Drug Info IC50 = 0.2 nM [1]
Patent ID WO2010045402
Title Trpv1 Antagonists.
Abstract Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Applicant(s) Abbott Laboratories
Representative Drug(s) D02QJE Drug Info IC50 = 4 nM Click to Show More [1]
2 D0HS1D Drug Info IC50 = 5 nM [1]
Patent ID WO2010045401
Title Trpv1 Antagonists.
Abstract Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Applicant(s) Abbott Laboratories
Representative Drug(s) D0F4YX Drug Info IC50 = 4 nM Click to Show More [1]
2 D0NM3D Drug Info IC50 = 4 nM [1]
3 D0JK2N Drug Info IC50 = 5 nM [1]
4 D07JNJ Drug Info IC50 = 9 nM [1]
5 D0SD4G Drug Info IC50 = 10 nM [1]
Patent ID WO2013068464
Title Substituted Pyrazolyl-Based Carboxamide and Urea Derivatives Bearing A Phenyl Moiety Substituted with An So2-Containing Group As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a S02-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D0OA1P Drug Info IC50 = 4 nM [1]
Patent ID WO2013068463
Title Substituted Pyrazolyl-Based Carboxamide and Urea Derivatives Bearing A Phenyl Moiety Substituted with An N-Cyclic Group As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an N-cyclic group as vanilloid receptor ligands formula (S) to pharmaceutical compositions containing these compounds of the general formula (S) and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Patent ID WO2013045452
Title Substituted Methanesulfonamide Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted methanesulfonamide derivatives as vanilloid receptor ligands of formula (I), to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Applicant(s) Gruenenthal Gmbh
Patent ID WO2012062463
Title Substituted Bicyclic Carboxamide and Urea Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted bicyclic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.
Applicant(s) Gruenenthal Gmbh
Representative Drug(s) D0B0WJ Drug Info IC50 = 7.7 nM [1]
Patent ID WO2012062462
Title Substituted Heteroaromatic Carboxamide and Urea Derivatives As Vanilloid Receptor Ligands.
Abstract The invention relates to substituted heteroaromatic carboxamide and urea derivatives of formula (I), to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.
Applicant(s) Gruenenthal Gmbh
Patent ID WO2012022487
Title Substituted Cyclic Carboxamide and Urea Derivatives As Ligands of The Vanilloid Receptor.
Abstract The invention relates to substituted cyclic carboxamide and urea derivatives, to processes for their preparation, to pharmaceuticals containing these compounds, and to the use of these compounds for the preparation of pharmaceuticals.
Applicant(s) Frank, Robert et al
Representative Drug(s) D0G3UV Drug Info IC50 = 10 nM [1]
United States Patent and Trademark Office (USPTO)
Patent ID US20148889690
Title Trpv1 Antagonists Including Dihydroxy Substituent and Uses Thereof.
Applicant(s) Purdue Pharma Lp
Representative Drug(s) D01RUK Drug Info IC50 = 38.7 nM [1]
Patent ID US20148673895
Title Tetrahydropyrimidoazepines As Modulators of Trpv1.
Applicant(s) Janssen Pharmaceutica Nv
Representative Drug(s) D01HED Drug Info IC50 = 18 nM Click to Show More [1]
2 D0N0TF Drug Info IC50 = 25 nM [1]
3 D0NV2M Drug Info IC50 = 32 nM [1]
4 D0K3KE Drug Info IC50 = 49 nM [1]
Patent ID US20148637527
Title Imidazolo-, Oxazolo-, and Thiazolopyrimidine Modulators of Trpv1.
Applicant(s) Janssen Pharmaceutica Nv
Representative Drug(s) D0LA0Q Drug Info IC50 = 6 nM Click to Show More [1]
2 D0I3ZW Drug Info IC50 = 8 nM [1]
Patent ID US20130243711
Title Novel Trpv1 Inhibitory Peptides and Composition for Skin-Aging Protection or Wrinkle Improvement Comprising The Same.
Applicant(s) Snu R & Db Foundation
Representative Drug(s) D03SHM Drug Info IC50 = 1.3 to 100 nM Click to Show More [1]
2 D05ZWR Drug Info IC50 = 1.3 to 100 nM [1]
Patent ID US20128173841
Title Tetrahydro-Naphthalene Derivatives.
Applicant(s) Xention Ltd
Representative Drug(s) D00OLY Drug Info IC50 <= 100 nM Click to Show More [1]
2 D0JT8B Drug Info IC50 <= 100 nM [1]
3 D0K3KM Drug Info IC50 <= 100 nM [1]
4 D0N0QN Drug Info IC50 <= 100 nM [1]
Patent ID US20120184571
Title Quinazolinone Derivatives Useful As Vanilloid Antagonists.
Applicant(s) Novartis Ag
Representative Drug(s) D02JQB Drug Info IC50 = 4 to 30000 nM Click to Show More [1]
2 D07XZR Drug Info IC50 = 4 to 30000 nM [1]
3 D08UEC Drug Info IC50 = 4 to 30000 nM [1]
4 D0CR0H Drug Info IC50 = 4 to 30000 nM [1]
5 D0K0ZI Drug Info IC50 = 4 to 30000 nM [1]
6 D0KM0W Drug Info IC50 = 4 to 30000 nM [1]
7 D0NH2M Drug Info IC50 = 4 to 30000 nM [1]
8 D0O3TG Drug Info IC50 = 4 to 30000 nM [1]
9 D0RC7L Drug Info IC50 = 4 to 30000 nM [1]
Patent ID US20120115827
Title 3-Aminobenzamide Compounds and Vanilloid Receptor Subtype 1 (Vr1) Inhibitors.
Applicant(s) Japan Tobacco, Inc
Representative Drug(s) D03FSF Drug Info IC50 <= 100 nM Click to Show More [1]
2 D07BZW Drug Info IC50 <= 100 nM [1]
3 D08ZBB Drug Info IC50 <= 100 nM [1]
4 D09QXC Drug Info IC50 <= 100 nM [1]
5 D0B4NI Drug Info IC50 <= 100 nM [1]
6 D0CX4C Drug Info IC50 <= 100 nM [1]
7 D0DC4O Drug Info IC50 <= 100 nM [1]
8 D0DE5I Drug Info IC50 <= 100 nM [1]
9 D0EC3Z Drug Info IC50 <= 100 nM [1]
10 D0H4TR Drug Info IC50 <= 100 nM [1]
11 D0H6CX Drug Info IC50 <= 100 nM [1]
12 D0OC6A Drug Info IC50 <= 100 nM [1]
13 D0QP4N Drug Info IC50 <= 100 nM [1]
Patent ID US20110212952
Title 3,4-Dihydrobenzoxazine Compounds and Inhibitors of Vanilloid Receptor Subtype 1 (Vr1) Activity.
Applicant(s) Japan Tobacco, Inc
Representative Drug(s) D03EEA Drug Info IC50 = 0.019 nM Click to Show More [1]
2 D0GV5G Drug Info IC50 = 0.024 nM [1]
3 D03YFL Drug Info IC50 = 0.15 nM [1]
4 D0E8UP Drug Info IC50 = 0.69 nM [1]
Patent ID US20110152318
Title Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof As Vanilloid Receptor Antagonist and Pharmaceutical Compositions Containing The Same.
Applicant(s) Amorepacific Corp
Representative Drug(s) D01DNH Drug Info IC50 = 30 nM Click to Show More [1]
2 D04TIU Drug Info IC50 = 42 nM [1]
3 D0AQ3U Drug Info IC50 = 45 nM [1]
Patent ID US20120184509
Title Compounds As Trvp1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof.
Representative Drug(s) D0R2VB Drug Info IC50 = 0.5 nM Click to Show More [1]
2 D0D4NX Drug Info IC50 = 2.3 nM [1]
Patent ID US20148716272
Title N-(Amino-Heteroaryl)-1Hpyrrolopyridine-2-Carboxamides Derivatives Preparation Thereof and Their Use In Therapy.
Applicant(s) Sanofi
Representative Drug(s) D01GEK Drug Info N.A. Click to Show More [1]
2 D07RYM Drug Info N.A. [1]
Patent ID US20128288376
Title Tricyclic N-Heteroarylcarboxamide Derivatives Containing A Benzimidazole Unit, Method for Preparing Same and Their Therapeutic Use.
Applicant(s) Sanofi-Aventis
Representative Drug(s) D07MNI Drug Info N.A. Click to Show More [1]
2 D09SMA Drug Info N.A. [1]
3 D0DI1R Drug Info N.A. [1]
4 D0PJ8O Drug Info N.A. [1]
Patent ID US20148765733
Title Amine Substituted Methanesulfonamide Derivatives As Vanilloid Receptor Ligands.
Applicant(s) Grunenthal Gmbh
Representative Drug(s) D0P0MR Drug Info IC50 = 4 nM [1]
Patent ID US20148637548
Title Therapeutic Agents Useful for Treating Pain.
Applicant(s) Purdue Pharma Lp
Representative Drug(s) D0MY3K Drug Info IC50 = 19 nM [1]
Patent ID US20130345255
Title Trpv1 Antagonists.
Applicant(s) Abbvie, Inc
Representative Drug(s) D0N2UQ Drug Info IC50 = 54 nM [1]
References  Top
REF 1 Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.